FDA Session Review: Dr. Arthur Kavanaugh Save
Dr. Kavanaugh discussed the FDA session presented at the ACR21 annual meeting, including safety data and new approvals and indications in several rheumatic diseases, including lupus, ANCA-associated vasculitis, lupus nephritis and more.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.